Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows in line with its trailing trend
Q3 FY2026 selling, general & admin of $366.3M rose 25.6% year over year, ahead of the +24.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Selling, general & admin amounted to 40.4% of revenue in FY2025, down 2.3 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 18 analysts of $1.85B (+60.2%) for the fiscal year ending Dec 2026, a step up from the +14.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $366.3M-16.7% QoQ
- Last fiscal yearDec 2025
- $1.16B+14.8% YoY
- LTMSep 2026
- $1.43B+24.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.16B USD
- Year-over-year change
- +14.8%
- 4-year CAGR
- +18.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.16B | +14.8% |
| FY2024 | 2024-12-31 | 1.01B | +13.5% |
| FY2023 | 2023-12-31 | 887.6M | +17.9% |
| FY2022 | 2022-12-31 | 752.7M | +29.0% |
| FY2021 | 2021-12-31 | 583.3M | — |
Selling, General & Admin vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's LTM Sep 2026 selling, general & admin of $1.43B is the 2nd highest of the 10 companies compared; the peer median is $256.23M.
- Its year-over-year change of +24.9% is the 6th highest of 10, against a peer median of +35.6%.
- Selling, general & admin amounts to 38.5% of revenue for NBIX, versus a peer median of 79.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.56B | -12.2% | +8.5% | 33.0% | |
| LTM Sep 2026 | $1.43B | +24.9% | +15.4% | 38.5% | |
| LTM Jun 2026 | $712.67M | +55.0% | +53.0% | 91.8% | |
| LTM Sep 2026 | $646.09M | +23.5% | +14.1% | 53.7% | |
| LTM Jun 2026 | $560.88M | +68.6% | +8.8% | 67.5% | |
| LTM Mar 2026 | $256.23M | +54.0% | +20.4% | 117.7% | |
| LTM Jun 2026 | $99.69M | -4.4% | -6.7% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $23.07M | +35.6% | +29.0% | — | |
| Peer median (excluding NBIX) | $256.23M | +35.6% | +20.4% | 79.7% | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B |
| Cost of Revenue | 14.3M | 23.2M | 39.7M | 34M | 52.1M |
| Gross Profit | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B |
| Gross Margin | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Research & Development | 328.1M | 463.8M | 565M | 731.1M | 1.02B |
| Selling, General & Admin | 583.3M | 752.7M | 887.6M | 1.01B | 1.16B |
| Operating Expenses | 1.02B | 1.22B | 1.6B | 1.75B | 2.19B |
| Depreciation & Amortization | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M |
| EBITDA | 138.1M | 236.6M | 416.1M | 639.7M | 666.6M |
| EBITDA Margin | 12.2% | 15.9% | 22.0% | 27.2% | 23.3% |
| Operating Income | 102.5M | 249M | 250.9M | 570.5M | 619.1M |
| Operating Margin | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Interest Income | 0 | 11.2M | 0 | 91M | 90.3M |
| Interest Expense | 25.8M | 7.1M | 4.6M | 126.6M | 0 |
| Other Income / Expenses | (1.1M) | (35.1M) | 81.2M | (84.5M) | 86.3M |
| Income Before Tax | 101.4M | 213.9M | 332.1M | 486M | 705.4M |
| Pre-Tax Margin | 8.9% | 14.4% | 17.6% | 20.6% | 24.7% |
| Income Tax Expense | 11.8M | 59.4M | 82.4M | 144.7M | 226.8M |
| Net Income | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M |
| Net Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (Basic) | 0.95 | 1.61 | 2.56 | 3.40 | 4.81 |
| EPS (Diluted) | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 |
| Weighted Avg Shares | 94.6M | 95.8M | 97.7M | 100.4M | 99.5M |
| Weighted Avg Shares (Diluted) | 97.9M | 98.9M | 101M | 103.7M | 102.5M |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.